Nearly all surveyed drug sellers (i.e. pharmacists) in the capital city of Seoul indicated a decrease, whether small or large, in outpatient prescriptions following the COVID-19 outbreak in South Korea in early 2020. This trend matches that of most other regions in Korea. Only a small share of four percent of the pharmacists in Seoul said there had been no change or even increases in prescriptions. This decrease is attributed to fewer hospital visits in the midst of the COVID-19 crisis.
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$189 USD $149 USD / Month *
in the first 12 months
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Impact of COVID-19 on revenue of hospitality and retail sector South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gwangju and Jeolla South Korea 2020
- Premium Statistic Impact of COVID-19 on OTC pharmacy sales South Korea 2020
- Premium Statistic Adjusted pharmaceutical sales forecast in South Korea 2020, by drug type
- Premium Statistic Merck & Co - expenditure on research and development 2006-2022
- Basic Statistic Revenue of leading European pharmaceutical markets 2021
- Premium Statistic Impact of COVID-19 on inbound tourist arrivals South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gyeonggi/Incheon/Gangwon South Korea 2020
About the region
10
- Basic Statistic Moderna net income 2016-2022
- Basic Statistic R&D expenses of Moderna 2016-2022
- Basic Statistic Moderna Inc collaboration revenue by related party 2018-2022
- Basic Statistic R&D expenses of Moderna by type 2022
- Basic Statistic Moderna's revenue 2016-2022
- Basic Statistic Moderna total assets 2016-2022
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Premium Statistic Amgen's expenditure on research and development 2006-2022
- Basic Statistic Number of COVID-19 drugs in development worldwide by phase June 2022
- Basic Statistic Leading COVID-19 drugs, therapies and vaccines in development by early results 2020
Selected statistics
10
- Basic Statistic Merck & Co total assets 2009-2022
- Basic Statistic GSK's operating profit by division 2006-2021
- Basic Statistic Sanofi's total assets 2007-2022
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2022
- Basic Statistic Merck & Co cash dividends declared 2006-2022
- Premium Statistic Sales of Johnson & Johnson 2006-2022 by region
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2022
- Premium Statistic Johnson & Johnson's number of employees 2004-2022
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2022, by segment
- Premium Statistic Global pharmaceutical pipeline by therapy area 2013-2017
Other regions
10
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Premium Statistic Leading European pharmaceutical companies by R&D spending 2022
- Basic Statistic Revenue of pharmaceutical markets in Central and Eastern Europe 2021
- Basic Statistic Number of biotechnology patents in Denmark 2011-2020
- Premium Statistic Revenue value from biotechnology companies in Germany 2008-2021
- Premium Statistic Canada's biologic share of pharmaceutical sales 2009-2018
- Basic Statistic Expedited drug approvals by firms from California 2014-2019
- Premium Statistic Biotechnology industry current expenses in Spain 2020, by nature of the expense
- Premium Statistic LabCorp number of employees 2014-2022
- Basic Statistic Revenues of Swiss biotech companies 2015-2022
Related statistics
10
- Premium Statistic Changes in outpatient prescriptions in Daegu and Gyeongbuk South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Daejeon and Chungcheong South Korea 2020
- Premium Statistic Impact of COVID-19 on pharmacy operations in South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Busan and Gyeongnam South Korea 2020
- Premium Statistic Traditional medicine industry South Korea 2021, by sales revenue
- Premium Statistic Traditional medicine industry sales in South Korea 2021, by sector
- Premium Statistic Pharmaceuticals market size South Korea 2008-2021
- Premium Statistic Number of companies in biotech industry in South Korea 2021, by sector
- Premium Statistic R&D investment value in biotech industry in South Korea 2021, by sector
- Premium Statistic Revenue of Celltrion 2013-2021
Further related statistics
10
- Key figures on established biotech centers worldwide 2012-2016
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- M&A capacities - changes for the global pharma industry 2008-2015
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2022
- MorphoSys' revenue 2006-2022
- Pfizer's ad spending 2008-2022
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
Further Content: You might find this interesting as well
Statistics
- Key figures on established biotech centers worldwide 2012-2016
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- M&A capacities - changes for the global pharma industry 2008-2015
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2022
- MorphoSys' revenue 2006-2022
- Pfizer's ad spending 2008-2022
- AstraZeneca's revenue from top product Pulmicort 2006-2022
- CVS Health's total assets 2005-2022
IQVIA. (March 31, 2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020 [Graph]. In Statista. Retrieved September 22, 2023, from https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/
IQVIA. "Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020." Chart. March 31, 2020. Statista. Accessed September 22, 2023. https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/
IQVIA. (2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020. Statista. Statista Inc.. Accessed: September 22, 2023. https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/
IQVIA. "Changes in Hospital Outpatient Prescriptions since Covid-19 Outbreak in Seoul in South Korea in 2020." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/
IQVIA, Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020 Statista, https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/ (last visited September 22, 2023)
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Seoul in South Korea in 2020 [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120091/south-korea-changes-in-outpatient-prescriptions-during-covid-19-seoul/